THE EFFECTIVENESS, IMMUNOGENICITY, AND SAFETY OF THE Escherichia coli BASED BIVALENT HUMAN PAPILLOMAVIRUS (TYPES 16 AND 18) VACCINE PREVENTING CERVICAL CANCER
A Systematic Review
DOI:
https://doi.org/10.53366/jimki.v11i3.795Keywords:
Escherichia coli, efficacy, human papillomavirus vaccine, immunogenicity, safetyAbstract
Background: Cervical cancer is the fourth most prevalent cancer worldwide and ranks second in Indonesia, with a high mortality rate among women. Cervical cancer ranks highest in treatment costs in Indonesia. HPV-16/18 infection causes nearly all cases of cervical cancer. The HPV-16/18 bivalent vaccine made with E. coli holds potential as a more affordable HPV vaccine than other commercial vaccines.
Objective: This systematic review aimed to discuss the effectiveness, immunogenicity, and safety of the bivalent HPV-16/18 vaccine produced by E. coli based on evidence from available studies.
Methods: This systematic review included valid experimental studies retrieved from PubMed, Cochrane, ScienceDirect, and Taylor and Francais databases that met the inclusion criteria. The search method used Boolean operators, with the literature cited from 2014 to 2024.
Results and Discussion: Seven studies met the inclusion criteria. The results of all studies indicate that the bivalent HPV-16/18 vaccine produced by E. coli has a high effectiveness and good immunogenicity. There were no significant side effects associated with vaccination, and most of the side effects were minor.
Conclusion: The bivalent HPV-16/18 vaccine produced by E. coli could serve as a reliable and economical alternative to prophylactic HPV vaccination for cervical cancer prevention.
References
2. International Agency for Research on Cancer. GLOBOCAN 2020: Indonesia [Internet]. https://gco.iarc.fr/. World Health Organization; 2021 [cited 2024 Feb 29]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
3. Andriani Y, Kristina SA, Wiedyaningsih C. Estimasi Biaya Pengobatan Langsung Penyakit Kanker di Indonesia: Estimasi Direct Medical Cost (DMC). Majalah Farmaseutik. 2021;17(3):251–5.
4. BPJS Kesehatan. BPJS Kesehatan Dorong Faskes Optimalkan Pelayanan untuk Pasien Kanker. 2021 [cited 2024 Feb 29]; Available from: https://bpjs-kesehatan.go.id/bpjs/post/read/2021/2061/BPJS-Kesehatan-Dorong-Faskes-Optimalkan-Pelayanan-untuk-Pasien-Kanker
5. Chen Q, Zhao H, Yao X, Lin Z, Li J, Lin B, et al. Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages. Vaccine. 2020 Sep 3;38(39):6096–102.
6. Zou Z, Fairley CK, Ong JJ, Hocking J, Canfell K, Ma X, et al. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. The Lancet Glob Health. 2020;8(10):1335–44.
7. Chen Y, Liu Y, Zhang G, Wang A, Dong Z, Qi Y, et al. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic. Virus Res. 2016;220:97–103.
8. Qiao YL, Wu T, Li RC, Hu YM, Wei LH, Li CG, et al. Efficacy, safety, and immunogenicity of an escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial. J Natl Cancer Inst. 2020;112(2):145–53.
9. Zhao FH, Wu T, Hu YM, Wei LH, Li MQ, Huang WJ, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Lancet Infect Dis. 2022;22(12):1756–68.
10. Hu YM, Guo M, Li CG, Chu K, He WG, Zhang J, et al. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women. Sci China Life Sci. 2020;63(4):582–91.
11. Wu T, Hu YM, Li J, Chu K, Huang SJ, Zhao H, et al. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial. Vaccine. 2015;33(32):3940–6.
12. Su YY, Lin BZ, Zhao H, Li J, Lin ZJ, Qiao YL, et al. Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial. Hum Vaccin Immunother. 2020;16(7):1636–44.
13. Yao X, He W, Wu X, Gu J, Zhang J, Lin B, et al. Long-Term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls. Hum Vaccin Immunother. 2022;18(5).
14. Yu XJ, Li J, Lin ZJ, Zhao H, Lin BZ, Qiao YL, et al. Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals. Hum Vaccin Immunother. 2020;16(7):1630–5.
15. Gupta SM, Mania-Pramanik J. Molecular mechanisms in progression of HPV-associated cervical carcinogenesis. Vol. 26, Journal of Biomedical Science. 2019;26(1).
16. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human Papillomavirus and Cervical Cancer. Lancet. 2013;382(9895):889–99.
17. Song D, Li H, Li H, Dai J. Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer (Review). Vol. 10, Oncology Letters. 2015. p. 600–6.
18. Stark H, Zivkovi? A. HPV Vaccination: Prevention of Cervical Cancer in Serbia and in Europe. Vol. 35, Acta Facultatis Medicae Naissensis. 2018. p. 5–16.
19. Yousefi Z, Aria H, Ghaedrahmati F, Bakhtiari T, Azizi M, Bastan R, et al. An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy. Vol. 12, Frontiers in Immunology. 2022;12.
20. Markowitz LE, Schiller JT. Human Papillomavirus Vaccines. Journal of Infectious Diseases. 2021;224:S367–78.
21. Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Vol. 471, Cancer Letters. 2020;471:88–102.
22. Hu YM, Huang SJ, Chu K, Wu T, Wang ZZ, Yang CL, et al. Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 viruslike particle vaccine An open-label phase i clinical trial. Hum Vaccin Immunother. 2014;10(2):469–75.
23. Akhatova A, Azizan A, Atageldiyeva K, Ashimkhanova A, Marat A, Iztleuov Y, et al. Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State. Vaccines. 2022;10(11):1912.
24. GAVI. Human Papillomavirus Vaccine Support [Internet]. 2018 [cited 2024 Feb 29]. Available from: https://www.gavi.org/types-support/vaccine-support/human-papillomavirus
25. World Health Organization. Global Market Study HPV [Internet]. www.who.int. World Health Organization; 2022 [cited 2024 Feb 29]. Available from: https://cdn.who.int/media/docs/default-source/immunization/mi4a/who-hpv-vaccine-global-market-study-april-2022.pdf
Additional Files
Published
Issue
Section
License
Copyright (c) 2025 Umar Jundullah Masykur, Karensa Abby Janet
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.